SEARCH

SEARCH BY CITATION

References

  • 1
    Tang ZY. Review. In: TangZY, ed. Tang ZY's clinical hepatocellular carcinoma. 1st ed. Shanghai, China: Shanghai Scientific and Technological Education Publishing House, 2001: 735.
  • 2
    Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, et al. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 187196.
  • 3
    Reid AE, Liang TJ. Tumor marker for metastasis: searching for an abnormal needle in a haystack. HEPATOLOGY 1994; 20: 16311634.
  • 4
    Chuma M, Saeki N, Yamamoto Y, Ohta T, Asaka M, Hirohashi S, et al. Expression profiling in hepatocellular carcinoma with intrahepatic metastasis: identification of high-mobility group I(Y) protein as a molecular marker of hepatocellular carcinoma metastasis. Keio J Med 2004; 53: 9097.
  • 5
    Koo J, Fung K, Siu KF, Lee NW, Lett Z, Ho J, Wong J, et al. Recovery of malignant tumor cells from the right atrium during hepatic resection for hepatocellular carcinoma. Cancer 1983; 52: 19521956.
  • 6
    Jeng KS, Sheen IS, Tsai YC. Does the presence of circulating hepatocellular carcinoma cells indicate a risk of recurrence after resection? Am J Gastroenterol 2004; 99: 15031509.
    Direct Link:
  • 7
    Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 15321538.
  • 8
    Van Thiel DH, Carr B, Iwatsuki S, Selby RR, Fung JJ. The 11-year Pittsburgh experience with liver transplantation for hepatocellular carcinoma: 1981–1991. J Surg Oncol 1993; 3( suppl): 7882.
  • 9
    Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 1991; 110: 726734.
  • 10
    Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693699.
  • 11
    International Union Against Cancer (UICC): TNM classification of malignant tumors. In: SobinLH, WittekindCH, eds. New York: Wiley-Liss, 1997: 7477.
  • 12
    Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002; 8: 873883.
  • 13
    Yao FY, Bass NM, Nikolai B, Merriman R, Davern TJ, Kerlan R, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003; 9: 684692.
  • 14
    Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. HEPATOLOGY 2001; 33: 13941403.
  • 15
    Bechstein WO, Guckelberger O, Kling N, Rayes N, Tullius SG, Lobeck H, et al. Recurrence-free survival after liver transplantation for small hepatocellular carcinoma. Transpl Int 1998; 11( Suppl 1): S189S192.
  • 16
    Chen ZN, Liu YF. Monoclonal antibody HAb18 to human hepatoma. Monoclonal Antibodies 1990; 8: 11.
  • 17
    Liu YF, Chen ZN, Ji YY. Localization of hepatocellular carcinoma with monoclonal antibodies. Zhonghua Yi Xue Za Zhi 1991; 71: 362365.
  • 18
    Chen ZN, Xing JL, Zhang SH, inventors; NTD patent & trademark agency Ltd., Beijing office, assignee. Anti-human hepatoma monoclonal antibody HAb18 light/heavy chain variable region gene, and use thereof. Chinese patent ZL02114471.0, 2002 March 15;PCT international patent WO03/078469. 2003 March 17.
  • 19
    Chen ZN, Mi L, Xu J, Song F, Zhang Q, Zhang Z, et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) Metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys 2006; 65: 435444.
  • 20
    Zhang Z, Bian HJ, Feng Q, Mi L, Mo TS, Kuang AN, et al. Biodistribution and Localization of Iodine-131 Labeled Metuximab in Patients with Hepatocellular Carcinoma. Cancer Biol Ther 2006; 5: 318322.
  • 21
    Toole BP. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol 2003; 54: 371389.
  • 22
    Chen ZN, Shang P, Li Y, Qian AR, Zhu P, Xing JL, inventors; NTD patent & trademark agency Ltd., Beijing office, assignee. HAb18G/CD147, it's agonist and application. Chinese patent ZL01131735.3, 2001 Sep 28;PCT international patent WO02/094875. 2002 May 27.
  • 23
    Zhang Q, Zhou J, Ku XM, Chen XG, Zhang L, Xu J, et al. Expression of CD147 as a significant unfavorable prognostic factor in hepatocellular carcinoma. Eur J Cancer Prev 2007, in press.
  • 24
    Zhang Q, Chen XG, Zhou J, Zhang L, Zhao QC, Chen GS, et al. CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther 2006; 5: 808814.
  • 25
    Jiang JL, Zhou Q, Yu MK, Ho LS, Chen ZN, Chan HC. The involvement of HAb18G/CD147 in regulation of store-operated calcium entry and metastasis of human hepatoma cells. J Biol Chem 2001; 76: 4687046877.
  • 26
    Huang Y, Jiang J, Dou K, Chen Z. HAb18G/CD147 enhances the secretion of matrix metalloproteinases (MMP) via cGMP/NO-sensitive capacitative calcium entry (CCE) and accordingly attenuates adhesion ability of fibroblasts. Eur J Cell Biol 2005; 84: 5973.
  • 27
    Jiang JL, Chan HC, Zhou Q, Yu MK, Yao XY, Lam SY, et al. HAb18G/CD147-mediated calcium mobilization and hepatoma metastasis require both C-terminal and N-terminal domains. Cell Mol Life Sci 2004; 61: 20832091.
  • 28
    Mi L, Chen ZN, Feng Q, Yu XL, inventors; Xi'an Tongda patent & trademark agency, assignee. Preparation of monoclonal antibody bivalent fragment and Fab fragment. Chinese patent ZL99115730.3. 1999 Mar 12.
  • 29
    Mi L, Li L, Feng Q, Yu XL, inventors; intellectual property services center of Shaanxi province, assignee. Technical methods of continuous perfusion culture hybridoma cells and CHO cells for production of monoclonal antibody. Chinese patent ZL01131736.1. 2001 Sep 29.
  • 30
    Mather SJ, Ward BG. High efficiency iodination of monoclonal antibodies for radiotherapy. J Nucl Med 1987; 28: 10341036.
  • 31
    Iida H, Honda M, Kawai HF, Yamashita T, Shirota Y, Wang BC, et al. Ephrin-A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing hepatocellular carcinoma. Gut 2005; 54: 843851.
  • 32
    Chen ZN, Liu YF, Jiang MD, Deng JL, Sui YF. Radiolocalization of human hepatoma with anti-human hepatoma monoclonal antibodies and its F(ab')2 in tumor-bearing nude mice. Zhonghua Yi Xue Za Zhi 1989; 69: 566568.
  • 33
    Chen ZN, Liu YF, Sui YF, Yang J, Deng J, Zhao, Y. Significance and application of anti-malignant hepatoma MAb HAb18 in radioimmunal diagnosis of human hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 1992; 14: 912.
  • 34
    Fung J, Marsh W. The quandary over liver transplantation for hepatocellular carcinoma: the greater sin? Liver Transpl 2002; 8: 775777.
  • 35
    Schwartz M, Roayaie S, Llovet J. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? J Hepatol 2005; 43: 584589.
  • 36
    Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 2004; 10: 449455.
  • 37
    Pokorny H, Gnant M, Rasoul-Rockenschaub S, Gollackner B, Steiner B, Steger G, et al. Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant 2005; 5: 788794.
  • 38
    Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003; 9: 557563.
  • 39
    Iwatsuki S, Starzl TE, Sheahan DG, Yokoyama I, Demetris AJ, Todo S, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991; 214: 221229.
  • 40
    Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003; 21: 43294335.
  • 41
    Song SB, Zhang TL, Xiu DR, Yuan J, Wang DC, Wang CM. Effective evaluation of liver transplantation for hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi 2004; 84: 15331535.
  • 42
    Cao XW, Fu ZR, Wang ZX, Li XX, Guo WY. Clinical analysis of 36 cases of primary Hepatocellular carcinoma with liver transplantation. Shi Yong Ai Zheng Za Zhi 2004; 19: 5961.
  • 43
    Kar S, Carr BI. Detection of liver cells in peripheral blood of patients with advanced-stage hepatocellular carcinoma. HEPATOLOGY 1995; 21: 403407.